HIV/AIDS
Panacos Announces Bevirimat Phase 2b Dose Escalation Strategy
Published in Food and Drug Law Weekly, March 30th, 2007
Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, announced that the Company and the US Food and Drug Administration (FDA) have agreed to a revised trial design for the Company's Phase 2b clinical study of bevirimat (PA-457), the first-in-class maturation inhibitor for the treatment of HIV infection. The first cohort in this study was completed in December, 2006 and confirmed the antiviral activity of bevirimat shown in previous studies and extended it to HIV patients failing therapy due to antiretroviral resistance. However, the prototype tablet formulation used in that cohort resulted in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
More Articles from Food and Drug Law Weekly
- Asthma
Safe Drug Compounding Act of 2007 Wins Favor with Consumer Health Alliance for Safe Medication - Drug Safety
National experts and nonprofit organizations call to end FDA user fees and to improve drug safety - Fibrosis
Retired Cleveland Businessman Sues Tyco International for Rare Disease Caused by its MRI Drug, Optimark Through Law Firm of Spangenberg, Shibley & Liber - Oncology
Senior Scientist from Johnson & Johnson Testifies Before Senate HELP Committee on Follow-On Biologics - Regulatory Actions
Genta Announces Closing of Common Stock Offering - Addiction Medicine
Scientists at National Institute of Public Health describe research in addiction medicine - More from this issue of Food and Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
